Perrigo, PFI, Granutec begin private label cimetidine/ranitidine promos to trade.
This article was originally published in The Tan Sheet
Executive Summary
PERRIGO, PFI, GRANUTEC START GENERIC CIMETIDINE/RANITIDINE PROMOS, beginning with the first big push to the trade at the Private Label Manufacturer's Association annual trade show in Chicago Nov. 16-19. The three generic drug companies are the first to begin marketing the next big private label OTC, the H2 antagonists, in anticipation of the termination of marketing exclusivity and the companies receiving ANDA approvals for generic versions of the drugs. Tagamet HB 200 (cimetidine) from SmithKline Beecham loses exclusivity June 19, and Glaxo Wellcome's Zantac 75 (ranitidine) loses marketing exclusivity Dec. 19, 1998.